GlassScriptPhysician profile
Michael C Peterson
NPI 1861542086
$6,009.70
in general payments reported to CMS, 2019-2025
31 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,704 · 2022: $682 · 2023: $1,147 · 2024: $938 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,624.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,058.70 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $725.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $590.23 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $581.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $405.35 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $376.30 | 2021-2025 | |
| Amgen INC. | $371.47 | 2021-2025 | Prolia, Evenity, Repatha |
| Phathom Pharmaceuticals, INC. | $223.91 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $222.68 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $176.08 | 2021-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Boston Scientific Corporation | $170.19 | 2023-2025 | General - Pain Management |
| Astellas Pharma US INC | $132.02 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.31 | 2021-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $98.20 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.44 | 2024-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91.58 | 2022-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $85.55 | 2021-2022 | |
| Abbott Laboratories | $75.81 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $71.42 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.54 | 2022 | |
| Janssen Pharmaceuticals, INC | $53.82 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.24 | 2021 | |
| Corcept Therapeutics | $38.57 | 2025 | Korlym |
| Antares Pharma, INC. | $33.70 | 2021-2024 | Xyosted |
| Tms Neurohealth Centers INC. | $25.01 | 2025 | Tms Neurohealth Centers INC. |
| Axsome Therapeutics, INC. | $19.48 | 2024 | Auvelity |
| Lundbeck LLC | $19.39 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $18.86 | 2023 | Thinprep 2000 Processor |
| Pacira Pharmaceuticals Incorporated | $14.92 | 2024 | Zilretta, Iovera |
| Clarus Therapeutics INC. | $12.96 | 2021 | |
| Radius Health, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.